MDR Therapeutics is developing a platform-based vaccine technology against bacterial pneumonia. The vaccines use components of bacterial outer membranes rather than polysaccharide capsules, and are designed to trigger mucosal T-cell and B-cell responses that give serotype-independent protection. [1]
The company is also working on needleless delivery so that its vaccines can be administered worldwide. Its targets include Streptococcus pneumoniae and gram-negative bacteria of the Enterobacteriaceae family. [1]